Nuvectis Pharma (NVCT) Stock Price, News & Analysis

Company Overview

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with cancer and other serious unmet medical needs. The company’s research and development programs are centered on novel small-molecule medicines designed to target biological pathways involved in tumor growth and treatment resistance.

Nuvectis’ lead product candidate, NXP800, is an orally administered investigational inhibitor of the heat shock factor 1 pathway. It is being evaluated in clinical studies for advanced solid tumors, including ovarian cancer and other tumor types in which this pathway may play a role. The company is also developing NXP900, an investigational small-molecule inhibitor of the Src and YES1 kinase family for potential use in advanced solid tumors.

Founded in 2021, Nuvectis Pharma is headquartered in Fort Lee, New Jersey, and conducts its development activities through clinical research and collaborations with medical institutions and research organizations. The company is led by Ron Bentsur, who serves as chairman and chief executive officer.

Key Stats

• Today's Range: $21.04 to $22.00
• 50-Day Range: $18.83 to $25.89
• 52-Week Range: $5.55 to $29.27
• Volume: 207,490 shs
• Average Volume: 199,515 shs
• Market Capitalization: $715.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.25
• Consensus Rating: Moderate Buy

Nuvectis Pharma Stock Analysis - MarketRank™

Nuvectis Pharma scored higher than 48% of companies evaluated by MarketBeat, and ranked 528th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nuvectis Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Nuvectis Pharma has a consensus price target of $36.25, representing about 65.4% upside from its current price of $21.92.

Amount of Analyst Coverage

Nuvectis Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Nuvectis Pharma are expected to decrease in the coming year, from ($1.01) to ($1.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuvectis Pharma is -16.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuvectis Pharma is -16.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuvectis Pharma has a P/B Ratio of 30.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.13% of the float of Nuvectis Pharma has been sold short.

Short Interest Ratio / Days to Cover

Nuvectis Pharma has a short interest ratio ("days to cover") of 14.77, which indicates bearish sentiment.

Change versus previous month

Short interest in Nuvectis Pharma has recently increased by 7.57%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuvectis Pharma does not currently pay a dividend.

Dividend Growth

Nuvectis Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.45

News Sentiment

Nuvectis Pharma has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Nuvectis Pharma this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for NVCT on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nuvectis Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.55% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NVCT
• CIK: 1875558
• Web: www.nuvectis.com
• Phone: 201-614-3150
• Fax: N/A
• Employees: 13
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Nuvectis Pharma: $36.25
• High Price Target: $40.00
• Low Price Target: $33.00
• Potential Upside/Downside: +65.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -184.25%
• Return on Assets: -105.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.68
• Quick Ratio: 1.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.72 per share
• Price / Book: 30.44

Miscellaneous

• Outstanding Shares: 32,640,000
• Free Float: 23,324,000
• Market Cap: $715.47 million
• Optionable: Not Optionable
• Beta: -0.24